We provide a one-stop-shop legal service for life sciences companies combining the firm’s strengths in all practice areas.
Our expertise cover wide range of life sciences products including pharmaceuticals, medical devices, food supplements, healthcare products and cosmetics.
We advise and represent trade organisations in the pharmaceutical and medical device sectors in relation to all local and international aspects of their field of activity and member interests, their relations with governmental organisations and peers, as well as establishing regulatory policies, position papers and the like.
We advise clients across all phases of the business cycle of life science products including clinical trials, marketing authorization procedures, pricing and reimbursement regulations, observational studies, promotional activities and ethical rules governing relations with healthcare professionals.
We advise and represent clients in life sciences sector in relation to all types of commercial transactions and contracts including licensing, technology transfer, co-marketing, co-promotion and toll manufacturing agreements, joint research, collaboration and development schemes as well as on data privacy and competition law issues.
Combining our life sciences expertise with our employment, competition and anti-corruption expertise, we support corporate clients in compliance with the FCPA and UKBA and the corresponding Turkish rules and regulations as well as offering compliance audits and training programs.
For references and your instructions please contact email@example.com
Amendment on the Decision on Pricing of Medicinal Products for Human Use
Gün + Partners, Articles, 22.11.2022
Decision on Pricing of Human Medicinal Products Amended
Practical Law Life Sciences Monthly Newsletter, Articles, 02.11.2022
Why Compulsory Licensing is a Blunt Instrument in the Post-Covid Landscape
IAM - International Report, Articles, 11.10.2022
New Reimbursement Regulation Published
Practical Law Life Sciences Monthly Newsletter, Articles, 05.10.2022
New Regulation on Drug Reimbursement has been Published
Gün + Partners, Articles, 04.10.2022
A Milestone Decision on the Patentability of Second Medical Use Claims
Kluwer Patent Blog, Articles, 16.08.2022
Drug Reimbursement Practices
Gün + Partners, Articles, 09.08.2022
Bolar-Like Hurdle for Generics
IAM - International Report, Articles, 09.08.2022
Neither a Compulsory License nor an IP Waiver is the Solution to Finding or Accessing the Vaccine
ManagingIP, Articles, 21.07.2022
SSI Publishes Amendment to the Alternative Reimbursement Regulation Upon Annulment of the State Council
Gün + Partners, Articles, 20.07.2022